NCT06101277 Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
| NCT ID | NCT06101277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Esophageal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-10-05 |
| Primary Completion | 2025-12-05 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Eligibility Criteria
Inclusion Criteria: 1. Must have one of the following histologically and/or biochemically confirmed cancers: 1. Cohort A: Esophageal, Gastroesophageal Junction, Gastric 2. Cohort B: Small bowel 3. Cohort C: Colorectal and appendiceal 4. Cohort D: Biliary including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma 5. Cohort E: Hepatocellular carcinoma 6. Cohort F: Pancreatic and ampullary 2. Provision of signed and dated informed consent form. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Age ≥18 years at time of consent. 5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy. 6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.